TW200503717A - Substituted 1,4-pyrazine derivatives - Google Patents
Substituted 1,4-pyrazine derivativesInfo
- Publication number
- TW200503717A TW200503717A TW092125064A TW92125064A TW200503717A TW 200503717 A TW200503717 A TW 200503717A TW 092125064 A TW092125064 A TW 092125064A TW 92125064 A TW92125064 A TW 92125064A TW 200503717 A TW200503717 A TW 200503717A
- Authority
- TW
- Taiwan
- Prior art keywords
- substituted
- pyrazine derivatives
- pyrazine
- derivatives
- depression
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41026102P | 2002-09-12 | 2002-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200503717A true TW200503717A (en) | 2005-02-01 |
Family
ID=31994096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092125064A TW200503717A (en) | 2002-09-12 | 2003-09-10 | Substituted 1,4-pyrazine derivatives |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040116444A1 (https=) |
| EP (1) | EP1539736A1 (https=) |
| JP (1) | JP2006506350A (https=) |
| AR (1) | AR041125A1 (https=) |
| AU (1) | AU2003269949A1 (https=) |
| BR (1) | BR0314139A (https=) |
| CA (1) | CA2494975A1 (https=) |
| MX (1) | MXPA05002418A (https=) |
| TW (1) | TW200503717A (https=) |
| WO (1) | WO2004024719A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099201A1 (en) * | 2003-05-09 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Compounds as crf1 receptor antagonists |
| US20060211710A1 (en) * | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| IL300091A (en) | 2018-05-01 | 2023-03-01 | Revolution Medicines Inc | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
| CN112368289B (zh) | 2018-05-01 | 2024-02-20 | 锐新医药公司 | 作为mtor抑制剂的c26-连接的雷帕霉素类似物 |
| AU2023275778A1 (en) | 2022-05-25 | 2024-12-12 | Revolution Medicines, Inc. | Methods of treating cancer with an mtor inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159980A (en) * | 1996-09-16 | 2000-12-12 | Dupont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
| PA8467401A1 (es) * | 1998-02-17 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para tratar la insuficiencia cardiaca |
| CO5271670A1 (es) * | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
| CN1231473C (zh) * | 2000-02-16 | 2005-12-14 | 神经能质公司 | 取代的芳基吡嗪 |
-
2003
- 2003-08-27 US US10/649,299 patent/US20040116444A1/en not_active Abandoned
- 2003-08-27 EP EP03751841A patent/EP1539736A1/en not_active Withdrawn
- 2003-08-27 CA CA002494975A patent/CA2494975A1/en not_active Abandoned
- 2003-08-27 JP JP2004536018A patent/JP2006506350A/ja not_active Abandoned
- 2003-08-27 AU AU2003269949A patent/AU2003269949A1/en not_active Abandoned
- 2003-08-27 WO PCT/US2003/024805 patent/WO2004024719A1/en not_active Ceased
- 2003-08-27 BR BR0314139-0A patent/BR0314139A/pt not_active IP Right Cessation
- 2003-08-27 MX MXPA05002418A patent/MXPA05002418A/es not_active Application Discontinuation
- 2003-09-02 AR ARP030103176A patent/AR041125A1/es unknown
- 2003-09-10 TW TW092125064A patent/TW200503717A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05002418A (es) | 2005-05-27 |
| US20040116444A1 (en) | 2004-06-17 |
| BR0314139A (pt) | 2005-07-12 |
| JP2006506350A (ja) | 2006-02-23 |
| AR041125A1 (es) | 2005-05-04 |
| AU2003269949A1 (en) | 2004-04-30 |
| CA2494975A1 (en) | 2004-03-25 |
| EP1539736A1 (en) | 2005-06-15 |
| WO2004024719A1 (en) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1446387E (pt) | Derivados de aril-1,4-pirazina substituídos | |
| MY130489A (en) | Substituted aryl 1, 4-pyrazine derivatives | |
| EP1583821A4 (en) | METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579 | |
| DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
| TW200503705A (en) | 3-amino chroman and 2-amino tetralin derivatives | |
| CA100209S (en) | Handle | |
| DE60237431D1 (de) | Rezeptor-selektive cannabimimetische aminoalkylindole | |
| AU2003299585A8 (en) | Water-soluble products and methods of making and using the same | |
| IL208191A0 (en) | Compositions and methods for treating rage-associated disorders | |
| IL164249A0 (en) | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use | |
| CA102775S (en) | Sponge | |
| MX2007002470A (es) | Fenilaminotiazoles sustituidos y su uso. | |
| TW200503717A (en) | Substituted 1,4-pyrazine derivatives | |
| EP1470240A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2 | |
| WO2003063796A3 (en) | Heterocyclic arylsulfonamidobenzylic compounds | |
| DK1220852T3 (da) | Substituerede diazepaner | |
| ZA200307306B (en) | Indolines, substituted in portion 6, and their use as kinase inhibitors. | |
| EP1476423A4 (en) | ARYLSULFONAMIDOBENZYLVERBINDUNGEN | |
| IL164887A0 (en) | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith | |
| TR200001102T2 (tr) | İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları. | |
| AU2003215190A8 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| NO20060420L (no) | 2-aminobenzoylderivater | |
| EP1471818A4 (en) | METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES | |
| CA102620S (en) | Sphygmomanometer |